Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits

Immunogenicity of TNF-Inhibitors

(2020) Sadaf Atiqi et al.   Frontiers in Immunology

Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues

(2020) Zhigang Wang et al.   CURRENT OPINION IN PHARMACOLOGY

P475 Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF-α maintenance therapy

(2019) S Facchin et al.   Journal of Crohns & Colitis

Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits

(2019) Emilio J. Laserna-Mendieta et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Harmonization and standardization of immunogenicity assessment of biotherapeutic products

(2019) Meenu Wadhwa et al.   Bioanalysis

Monitoring of infliximab trough levels and anti-infliximab antibodies in inflammatory bowel diseases: A comparison of three commercially available ELISA kits

(2019) Daniel Bertin et al.   CYTOKINE

Anti-infliximab antibodies: How to compare old and new data?

(2019) Maya Imbrechts et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Comparison of Point-of-Care and Classical Immunoassays for the Monitoring Infliximab and Antibodies Against Infliximab in IBD

(2018) Yara Nasser et al.   DIGESTIVE DISEASES AND SCIENCES

Proactively Optimized Infliximab Monotherapy Is as Effective as Combination Therapy in IBD

(2018) Sara Lega et al.   INFLAMMATORY BOWEL DISEASES

Detection of anti-adalimumab antibodies in a RA responsive cohort of patients using three different techniques

(2018) Feliciana Real-Fernández et al.   ANALYTICAL BIOCHEMISTRY

Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

(2017) Mônica Simon Prado et al.   Expert Opinion on Drug Metabolism & Toxicology

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial

(2017) Thomas Van Stappen et al.   GUT

P503 Rapid point-of-care monitoring of anti-infliximab antibodies in patients with inflammatory bowel disease treated with the reference infliximab or CT-P13 in routine clinical practice

(2017) A. Ametzazurra et al.   Journal of Crohns & Colitis

Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays

(2016) J. Afonso et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Immunogenicity Assessment of Tumor Necrosis Factor Antagonists in the Clinical Laboratory

(2016) E. Lazar-Molnar et al.   CLINICAL CHEMISTRY

Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay

(2016) Thomas Van Stappen et al.   Drug Testing and Analysis

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

(2016) Ann Gils et al.   INFLAMMATORY BOWEL DISEASES

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays

(2016) Joana Afonso et al.   Therapeutic Advances in Gastroenterology

Loss of Response to Anti-TNFs: Definition, Epidemiology and Management

(2016) Giulia Roda et al.   Clinical and Translational Gastroenterology

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

(2015) Shomron Ben-Horin et al.   GUT

Systematic comparison of drug-tolerant assays for anti-drug antibodies in a cohort of adalimumab-treated rheumatoid arthritis patients

(2015) Karien Bloem et al.   JOURNAL OF IMMUNOLOGICAL METHODS

State of the art paper Tumor necrosis factor inhibitors – state of knowledge

(2015) Krzysztof Lis et al.   Archives of Medical Science

Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

(2014) Casper Steenholdt et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization

(2014) Ann Gils et al.   THERAPEUTIC DRUG MONITORING

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY